GlassScriptPhysician profile
Donald Richard Lynch
NPI 1992762009
$590.13
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $43.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $127.43 | 2019 | |
| Astellas Pharma US INC | $119.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.59 | 2019 | |
| Amgen INC. | $59.00 | 2019 | |
| Genentech USA, INC. | $43.61 | 2019 | |
| Boston Scientific Corporation | $43.16 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $37.97 | 2019 | |
| Pfizer INC. | $16.80 | 2019 | |
| Valeritas, INC. | $16.11 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.89 | 2019 | |
| Shire North American Group INC | $14.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.